The National Agency for Food and Drug Administration and Control (NAFDAC) will issue an emergency use authorization (EUA) for Janssen Pharmaceutical Companies’ Covid-19 single-dose vaccines today.
This statement was released by the agency’s Director-General, Prof. Mojisola Adeyeye today. She mentioned that the evaluation by the NAFDAC Vaccine Committee concluded that the vaccine was good for use haven met the required standard for use in the country.
Nigeria bids to get 29.6million doses of the viral vector vaccine through the African Vaccine Acquisition Trust led by Afreximbank.
This is the third vaccine to be recommended for administration in the country. The Janssen vaccine got an emergency authorization by the U.S Food and Drug Administration (FDA) in February, after which the vaccine hit suspension and restrictions over alleged links to rare blood clots.
For example, Ireland has limited J&J vaccinations to people over the age of 50, while Denmark became the first country to exclude the shots from its vaccination program on May 3.
Countries have resumed use of the vaccine after the company found no direct causal association between the vaccine and clots and a study by the European Medicines Agency (EMA) concluded that the benefits outweigh any risks.
France, Germany, Greece, Italy Netherlands, Poland, Spain, Sweden, and the United States has resumed rolling out the vaccine also in April. The US Centre for Disease Control (CDC) and FDA on April 23 recommended the use of Johnson & Johnson’s vaccine resume.
According to her, the Janssen COVID-19 vaccine works by preparing the body to defend itself against COVID-19.
The NAFDAC director stated that the Janssen COVID-19 vaccine will be closely monitored and subjected to a number of activities tailored to COVID-19 vaccines. In addition to the daily updates provided by NAFDAC activities, she said the manufacturers were required to provide monthly safety reports.
According to Adeyeye, the Janssen COVID-19 vaccine works by preparing the body to defend itself against COVID-19.
Unopened vaccine vials can be stored and/or transported frozen at -25°C to – 15°C for up to 24 months and three months when stored at 2 to 8°C.
The Ministry of Health and the National Primary Health Care Development Agency will announce when the vaccine becomes available for use in Nigeria